[PDF][PDF] Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an …
Journal of Clinical Oncology, 2008•academia.edu
Purpose Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that inhibits vascular
endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, stem cell
factor receptor (KIT), and colony-stimulating factor-1 receptor. This phase II, open-label,
multicenter study evaluated sunitinib monotherapy in patients with metastatic breast cancer
(MBC).
endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, stem cell
factor receptor (KIT), and colony-stimulating factor-1 receptor. This phase II, open-label,
multicenter study evaluated sunitinib monotherapy in patients with metastatic breast cancer
(MBC).
Purpose
Sunitinib is an oral, multitargeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, stem cell factor receptor (KIT), and colony-stimulating factor-1 receptor. This phase II, open-label, multicenter study evaluated sunitinib monotherapy in patients with metastatic breast cancer (MBC).
academia.edu